美国 · SEC FORM 4
Nkarta, Inc.
NKTX · Nasdaq · CIK 0001787400 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
1 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-03-27 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 3,661,385
- 上期报告
- 3,506,533
- 日均成交量
- 621,738
- 回补天数
- 5.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-03-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 3,000,000 | USD 10.00 | USD 30,000,000 | SEC 申报 ↗ |
| 2024-03-27 | George Simeon | 买入 (P) | Common Stock | 2,000,000 | USD 10.00 | USD 20,000,000 | SEC 申报 ↗ |
| 2022-04-28 | George Simeon | 买入 (P) | Common Stock | 1,333,333 | USD 15.00 | USD 19,999,995 | SEC 申报 ↗ |
| 2022-04-26 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 2,200,000 | USD 15.00 | USD 33,000,000 | SEC 申报 ↗ |
| 2020-07-14 | Sonsini Peter W. | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | SANDELL SCOTT D | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | Novo Holdings A/S | 买入 (P) | COMMON STOCK | 555,555 | USD 18.00 | USD 9,999,990 | SEC 申报 ↗ |
| 2020-07-14 | NEA 15 GP, LLC; NEA Partners 15, L.P.; New Enterprise Associates 15, L.P. | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | Makhzoumi Mohamad | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | MAKOWER JOSHUA | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 3,333,333 | USD 18.00 | USD 59,999,994 | SEC 申报 ↗ |
| 2020-07-14 | GLAXOSMITHKLINE PLC | 买入 (P) | Common Stock | 833,333 | USD 18.00 | USD 14,999,994 | SEC 申报 ↗ |
| 2020-07-14 | Florence Anthony A. Jr. | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | BASKETT FOREST | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2020-07-14 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Mgmt L.P.; Deerfield Private Design Fund IV, L.P.; Flynn James E | 买入 (P) | Common Stock | 500,000 | USD 18.00 | USD 9,000,000 | SEC 申报 ↗ |
Form 4 申报证据
6 transaction lines in the latest 365-day window; 183 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | HASTINGS PAUL J | 卖出 (S) | Common Stock | 1,776 | USD 2.71 | USD 4,813 | SEC 申报 ↗ |
| 2026-01-15 | Mahmood Nadir | 卖出 (S) | Common Stock | 5,649 | USD 2.07 | USD 11,693 | SEC 申报 ↗ |
| 2026-01-15 | HASTINGS PAUL J | 卖出 (S) | Common Stock | 26,046 | USD 2.07 | USD 53,915 | SEC 申报 ↗ |
展开近期 Form 4 证据 (6 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | HASTINGS PAUL J | 卖出 (S) | Common Stock | 1,776 | USD 2.71 | USD 4,813 | SEC 申报 ↗ |
| 2026-01-15 | Mahmood Nadir | 卖出 (S) | Common Stock | 5,649 | USD 2.07 | USD 11,693 | SEC 申报 ↗ |
| 2026-01-15 | HASTINGS PAUL J | 卖出 (S) | Common Stock | 26,046 | USD 2.07 | USD 53,915 | SEC 申报 ↗ |
| 2026-01-06 | Rose Shawn Marshall | 奖励／授予 (A) | Common Stock | 70,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | Mahmood Nadir | 奖励／授予 (A) | Common Stock | 80,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | HASTINGS PAUL J | 奖励／授予 (A) | Common Stock | 94,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NKTX |
| CIK | 0001787400 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 183 transaction lines from 2020-07-14 to 2026-06-18 17 P purchase lines · 69 S sale lines · 97 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.